The most commonly reported side effects of mipomersen include injection site pain, injection site erythema, and hepatic enzyme increased, based on 287 FDA adverse event reports from 2013 to 2024.
Percentages show how often each reaction appears relative to total reports for mipomersen.
These are voluntary reports and do not establish that mipomersen caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside mipomersen. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
59.9% of mipomersen adverse event reports involve female patients and 37.6% involve male patients. The largest age group is adult at 74%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking mipomersen when the adverse event was reported.
Mipomersen is sold under the brand name Kynamro.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.